Pharma

Your Article Summary

See Latest Articles

BTG Licensee Cougar Biotechnology Initiates Phase I/II Trial of CB7630 (Abiraterone Acetate) in Advanced Breast Cancer
BTG, 01/09/09

BTG plc, the life sciences company, notes announcement by Cougar Biotechnology, Inc. that enrolment has commenced into a Phase I/II trial of CB7630 (abiraterone acetate) in patients with advanced breast cancer.

Today in Biotechnology...keeping you current

Receive free subspecialty "5-minute updates" via email

Sanofi-aventis and U.S Biotechnology company Alopexx enter into a collaboration agreement for a novel human monoclonal antibody targeting infectious diseases
Sanofi-aventis, 12/11/09

Quality by Design for Biotechnology Products—Part 2
BioPharm, 12/09/09

Amylin Pharmaceuticals to Present at the 2009 Deutsche Bank Biotech Boston Confab
Amylin Pharmaceuticals, 12/09/09

 See all of Biotechnology

Today in Research & Development...keeping you current

Receive free subspecialty "5-minute updates" via email

New study results presented at 2009 san antonio breast cancer symposium show importance of protecting your bones
Amgen, 12/11/09

Phase III CONFIRM study shows FASLODEX (fulvestrant) Injection 500 mg may delay time of disease progression over 250-mg dose in postmenopausal women with hormone receptor-positive advanced breast cancer
AstraZeneca, 12/11/09

Salix Pharmaceuticals Reports Concurrence with FDA on Content and Format of the Pending Rifaximin NDA in the Treatment of Non-Constipation Irritable Bowel Syndrome
Salix Pharmaceuticals, 12/11/09

 See all of Research & Development